|
1
|
Kaufmann E and Knöchel W: Five years on
the wings of fork head. Mech Dev. 57:3–20. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong XY, Chen C, Sun X, Guo P, Vessella
RL, Wang RX, Chung LW, Zhou W and Dong JT: FOXO1A is a candidate
for the 13q14 tumor suppressor gene inhibiting androgen receptor
signaling in prostate cancer. Cancer Res. 66:6998–7006. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu
F, Ethier SP, Miller F and Wu G: Forkhead transcription factor
Foxq1 promotes epithelial-mesenchymal transition and breast cancer
metastasis. Cancer Res. 71:1292–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi
SC and Yu Q: FOXQ1 regulates epithelial-mesenchymal transition in
human cancers. Cancer Res. 71:3076–3086. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van der Heul-Nieuwenhuijsen L, Dits N, Van
Ijcken W, de Lange D and Jenster G: The FOXF2 pathway in the human
prostate stroma. Prostate. 69:1538–1547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kong PZ, Yang F, Li L, Li XQ and Feng YM:
Decreased FOXF2 mRNA expression indicates early-onset metastasis
and poor prognosis for breast cancer patients with histological
grade II tumor. PLoS One. 8:e615912013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ormestad M, Astorga J, Landgren H, Wang T,
Johansson BR, Miura N and Carlsson P: Foxf1 and Foxf2 control
murine gut development by limiting mesenchymal Wnt signaling and
promoting extracellular matrix production. Development.
133:833–843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nik AM, Reyahi A, Pontén F and Carlsson P:
Foxf2 in intestinal fibroblasts reduces numbers of Lgr5+
stem cells and adenoma formation by inhibiting Wnt signaling.
Gastroenterology. 144:1001–1011. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guttilla IK and White BA: Coordinate
regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast
cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiang CH, Hou MF and Hung WC:
Up-regulation of miR-182 by β-catenin in breast cancer increases
tumorigenicity and invasiveness by targeting the matrix
metalloproteinase inhibitor RECK. Biochim Biophys Acta.
1830:3067–3076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Liu J, Segura MF, Shao C, Lee P,
Gong Y, Hernando E and Wei JJ: MiR-182 overexpression in
tumourigenesis of high-grade serous ovarian carcinoma. J Pathol.
228:204–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchiyama K, Ito H, Taga M, Naganuma S,
Oshinoya Y, Nagano K, Yokoyama O and Itoh H: Expression of
microRNAs associated with Gleason grading system in prostate
cancer: miR-182-5p is a useful marker for high grade prostate
cancer. Prostate. 73:827–834. 2013. View Article : Google Scholar
|
|
13
|
Segura MF, Hanniford D, Menendez S, et al:
Aberrant miR-182 expression promotes melanoma metastasis by
repressing FOXO3 and microphthalmia-associated transcription
factor. Proc Natl Acad Sci USA. 106:1814–1819. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lei R, Tang J, Zhuang X, Deng R, Li G, Yu
J, Liang Y, Xiao J, Wang HY, Yang Q and Hu G: Suppression of MIM by
microRNA-182 activates RhoA and promotes breast cancer metastasis.
Oncogene. 33:1287–1296. 2014. View Article : Google Scholar
|
|
15
|
Moskwa P, Buffa FM, Pan Y, et al:
miR-182-mediated downregulation of BRCA1 impacts DNA repair and
sensitivity to PARP inhibitors. Mol Cell. 41:210–220. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang
Q, Cheng P, Tang ZH and Huang F: Meta-analysis of microRNA-183
family expression in human cancer studies comparing cancer tissues
with noncancerous tissues. Gene. 527:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cekaite L, Rantala JK, Bruun J, et al:
MiR-9, -31, and -182 deregulation promote proliferation and tumor
cell survival in colon cancer. Neoplasia. 14:868–879.
2012.PubMed/NCBI
|
|
18
|
Sabates-Bellver J, Van der Flier LG, de
Palo M, et al: Transcriptome profile of human colorectal adenomas.
Mol Cancer Res. 5:1263–1275. 2007. View Article : Google Scholar
|
|
19
|
Jiang X, Tan J, Li J, et al: DACT3 is an
epigenetic regulator of Wnt/β-catenin signaling in colorectal
cancer and is a therapeutic target of histone modifications. Cancer
Cell. 13:529–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jorissen RN, Lipton L, Gibbs P, et al: DNA
copy-number alterations underlie gene expression differences
between micro-satellite stable and unstable colorectal cancers.
Clin Cancer Res. 14:8061–8069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smith JJ, Deane NG, Wu F, et al:
Experimentally derived metastasis gene expression profile predicts
recurrence and death in patients with colon cancer.
Gastroenterology. 138:958–968. 2010. View Article : Google Scholar
|
|
22
|
Watanabe T, Kobunai T, Toda E, et al:
Distal colorectal cancers with microsatellite instability (MSI)
display distinct gene expression profiles that are different from
proximal MSI cancers. Cancer Res. 66:9804–9808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsukamoto S, Ishikawa T, Iida S, Ishiguro
M, Mogushi K, Mizushima H, Uetake H, Tanaka H and Sugihara K:
Clinical significance of osteoprotegerin expression in human
colorectal cancer. Clin Cancer Res. 17:2444–2450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirata H, Ueno K, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p
promotes cell invasion and proliferation by down regulating FOXF2,
RECK and MTSS1 genes in human prostate cancer. PLoS One.
8:e555022013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang L, Mao P, Song L, Wu J, Huang J, Lin
C, Yuan J, Qu L, Cheng SY and Li J: miR-182 as a prognostic marker
for glioma progression and patient survival. Am J Pathol.
177:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun Y, Fang R, Li C, Li L, Li F, Ye X and
Chen H: Hsa-mir-182 suppresses lung tumorigenesis through down
regulation of RGS17 expression in vitro. Biochem Biophys Res
Commun. 396:501–507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarver AL, French AJ, Borralho PM, et al:
Human colon cancer profiles show differential microRNA expression
depending on mismatch repair status and are characteristic of
undifferentiated proliferative states. BMC Cancer. 9:4012009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu H, Du L, Wen Z, et al: Up-regulation
of miR-182 expression in colorectal cancer tissues and its
prognostic value. Int J Colorectal Dis. 28:697–703. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diep CB, Kleivi K, Ribeiro FR, Teixeira
MR, Lindgjaerde OC and Lothe RA: The order of genetic events
associated with colorectal cancer progression inferred from
meta-analysis of copy number changes. Genes Chromosomes Cancer.
45:31–41. 2006. View Article : Google Scholar
|
|
30
|
Wang T, Tamakoshi T, Uezato T, Shu F,
Kanzaki-Kato N, Fu Y, Koseki H, Yoshida N, Sugiyama T and Miura N:
Forkhead transcription factor Foxf2 (LUN)-deficient mice exhibit
abnormal development of secondary palate. Dev Biol. 259:83–94.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aitola M, Carlsson P, Mahlapuu M, Enerback
S and Pelto-Huikko M: Forkhead transcription factor FoxF2 is
expressed in mesodermal tissues involved in epithelio-mesenchymal
interactions. Dev Dyn. 218:136–149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirata H, Ueno K, Shahryari V, Tanaka Y,
Tabatabai ZL, Hinoda Y and Dahiya R: Oncogenic miRNA-182-5p targets
Smad4 and RECK in human bladder cancer. PLoS One. 7:e510562012.
View Article : Google Scholar : PubMed/NCBI
|
